BioArctic (BIOA B) Resumen de Acciones
BioArctic AB (publ) desarrolla en Suecia medicamentos biológicos para pacientes con trastornos del sistema nervioso central. Saber más
| Puntuación del snowflake | |
|---|---|
| Valoración | 0/6 |
| Crecimiento futuro | 6/6 |
| Rendimiento pasado | 2/6 |
| Salud financiera | 6/6 |
| Dividendos | 0/6 |
BIOA B Community Fair Values
Create NarrativeSee what 30 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Competidores de BioArctic AB (publ)
Historial de precios y rendimiento
| Precios históricos de las acciones | |
|---|---|
| Precio actual de la acción | SEK 312.20 |
| Máximo en las últimas 52 semanas | SEK 364.40 |
| Mínimo de 52 semanas | SEK 181.70 |
| Beta | -0.67 |
| Cambio en 1 mes | 3.24% |
| Variación en 3 meses | -8.66% |
| Cambio de 1 año | 68.57% |
| Variación en 3 años | 9.31% |
| Variación en 5 años | 131.26% |
| Variación desde la OPV | 976.55% |
Noticias y actualizaciones recientes
Actualización de narrativa • Jun 16
BIOA B: Future Returns Will Depend On Sustained NLRP3 Execution Risk
Analysts have maintained their SEK 240.00 price target on BioArctic, citing materially higher modeled revenue growth of 14.61% and a stronger 23.70% profit margin outlook, partly offset by a lower future P/E assumption of 61.02x. Analyst Commentary Recent research around BioArctic highlights a split view between optimism on the long term opportunity and caution on what is already reflected in the share price.
Actualización de narrativa • Jun 01
BIOA B: Alzheimer’s Access Delays And Nordic Rollout Will Shape Future Returns
Analysts now set their fair value estimate for BioArctic at SEK 363, down slightly from SEK 367. This reflects updated assumptions around revenue growth, profit margins and a lower future P/E multiple.Recent updates
Actualización de narrativa • Jun 16
BIOA B: Future Returns Will Depend On Sustained NLRP3 Execution Risk
Analysts have maintained their SEK 240.00 price target on BioArctic, citing materially higher modeled revenue growth of 14.61% and a stronger 23.70% profit margin outlook, partly offset by a lower future P/E assumption of 61.02x. Analyst Commentary Recent research around BioArctic highlights a split view between optimism on the long term opportunity and caution on what is already reflected in the share price.Actualización de narrativa • Jun 01
BIOA B: Alzheimer’s Access Delays And Nordic Rollout Will Shape Future Returns
Analysts now set their fair value estimate for BioArctic at SEK 363, down slightly from SEK 367. This reflects updated assumptions around revenue growth, profit margins and a lower future P/E multiple.Artículo de análisis • May 28
BioArctic's (STO:BIOA B) Soft Earnings Don't Show The Whole Picture
BioArctic AB (publ)'s ( STO:BIOA B ) stock was strong despite it releasing a soft earnings report last week. We think...Artículo de análisis • May 24
BioArctic AB (publ) Just Reported A Surprise Profit, And Analysts Lifted Their Estimates
As you might know, BioArctic AB (publ) ( STO:BIOA B ) recently reported its quarterly numbers. Revenues of 66% beat...Actualización de narrativa • May 18
BIOA B: Future Returns Will Depend On High NLRP3 Execution Risk
Analysts kept their SEK 240.00 price target for BioArctic unchanged, with slightly lower discount rate and profit margin assumptions, and a higher future P/E multiple that reflects refined views on the stock's risk profile and earnings power. Analyst Commentary Recent research on BioArctic has centered on how changing assumptions around risk, profitability, and long term earnings power feed into valuation.Actualización de narrativa • Apr 22
BIOA B: Future Returns Will Depend On High NLRP3 Execution Risk
Analysts have kept their SEK 240.0 price target for BioArctic unchanged, explaining the steady view by slightly adjusting discount rate, revenue growth, profit margin and future P/E assumptions, while balancing higher perceived risk with ongoing optimism around the broader NLRP3 and cardiovascular opportunity highlighted in recent peer research. Analyst Commentary Research coverage around NLRP3-targeted therapies has been active, with several firms updating their views and price targets on peers such as BioAge Labs.
Actualización de narrativa • Apr 08
BIOA B: NLRP3 Opportunity And Alzheimer’s Data Will Shape Balanced Outlook
The analyst fair value estimate for BioArctic has shifted from SEK 294.60 to SEK 303.80, with analysts pointing to more constructive views on the NLRP3 opportunity set and comparisons to bullish Street research on peers as key drivers behind the updated target assumptions. Analyst Commentary Bullish analysts are drawing parallels between BioArctic's NLRP3 exposure and Street enthusiasm around peers such as BioAge Labs, where recent research has highlighted NLRP3 programs and adjacent cardiovascular and ophthalmology opportunities as a key value driver.Actualización de narrativa • Mar 25
BIOA B: Future Earnings Will Depend On High China Access Risk
Analysts have nudged their fair value estimate for BioArctic to SEK240 from SEK236. This reflects updated assumptions around revenue contraction, profitability and a higher future P/E multiple, while keeping the discount rate broadly similar.Actualización de narrativa • Mar 10
BIOA B: China Alzheimer’s Access And Delivery Shift Will Drive Future Upside
Analysts are keeping their SEK 367.0 price target for BioArctic broadly unchanged, with only modest tweaks to underlying assumptions. They highlight parallels with recent bullish Street research on early stage biotech names that are seeing renewed interest around differentiated clinical assets.Actualización de narrativa • Feb 24
BIOA B: Peer Re-Rating And China Alzheimer’s Momentum Will Reframe Upside
Analysts have raised their BioArctic fair value estimate from SEK353 to SEK367 as they factor in updated views on revenue growth, margins, discount rate and a higher future P/E assumption aligned with recent bullish Street research on comparable biotech names. Analyst Commentary Recent Street research on comparable biotech names has turned more optimistic, with bullish analysts revisiting their models and price targets in light of updated clinical views and perceived market potential.Actualización de narrativa • Feb 09
BIOA B: Future Earnings Will Depend On Risky China Insurance Access
Analysts have raised their fair value estimate for BioArctic from SEK 230 to SEK 236, citing updated assumptions regarding discount rates, revenue growth, profit margins and a slightly higher future P/E multiple. Analyst Commentary Recent analyst work on comparable neurology and biotech names highlights how sensitive valuations can be to small shifts in assumptions around discount rates, revenue build, profitability and terminal P/E multiples.Actualización de narrativa • Jan 25
BIOA B: Future Earnings Will Rely On Risky China Alzheimer Access
Analysts now keep their price target for BioArctic at SEK 230.00, with small adjustments to the discount rate, revenue growth assumptions and future P/E outlook. This reflects only minor changes to their overall view of the company’s risk and profitability profile.Actualización de narrativa • Jan 09
BIOA B: Future Earnings Will Depend On Risky Alzheimer Access Rollout
Analysts have maintained their fair value estimate for BioArctic at SEK 230.00. They have, however, adjusted assumptions related to the discount rate, revenue trends, profit margins, and future P/E to reflect updated views on the company’s risk profile and earnings potential.Actualización de narrativa • Dec 26
BIOA B Future Long Term Margin Upside Will Not Offset Demand Risks
Analysts have modestly raised their price target on BioArctic to SEK 230 (from SEK 230 previously), reflecting slightly lower perceived risk and a substantially improved long term profit margin outlook, despite marginally weaker revenue growth assumptions and a lower projected future P/E multiple. What's in the News Leqembi, developed by BioArctic and Eisai, has been included in China’s new Commercial Insurance Innovative Drug List.Actualización de narrativa • Dec 12
BIOA B: Future Revenue Weakness Will Outweigh Expanding Alzheimer’s Market Approval
Analysts have reduced their price target on BioArctic from SEK 280 to SEK 230. This reflects a more cautious outlook on future revenue growth despite improved profitability expectations and a slightly higher discount rate.Artículo de análisis • Nov 16
BioArctic AB (publ) (STO:BIOA B) Just Released Its Third-Quarter Earnings: Here's What Analysts Think
It's been a pretty great week for BioArctic AB (publ) ( STO:BIOA B ) shareholders, with its shares surging 12% to kr295...Actualización de narrativa • Sep 17
Overhyped Valuations Will Falter Amid Healthcare Headwinds
Despite a significant improvement in BioArctic's net profit margin and a sharp decline in its future P/E multiple, the consensus analyst price target has been revised downward to SEK294.60. What's in the News FDA approved the Biologics License Application for weekly subcutaneous maintenance dosing of lecanemab (LEQEMBI IQLIK) for early Alzheimer's disease; U.S. launch set for October 6, 2025.Actualización de narrativa • Sep 02
Regulatory Approvals And Pipeline Progress Will Redefine Neurodegeneration Care
BioArctic's consensus price target has been reduced to SEK280.50, primarily due to sharply lower revenue growth expectations and a significant drop in the projected future P/E multiple. What's in the News BioArctic entered an option, collaboration, and license agreement with Novartis Pharma involving its proprietary BrainTransporter technology for a potential neurodegeneration treatment, receiving USD 30 million upfront, with up to USD 772 million in potential milestone payments and tiered royalties.Artículo de análisis • Aug 14
Revenues Not Telling The Story For BioArctic AB (publ) (STO:BIOA B) After Shares Rise 26%
OM:BIOA B 1 Year Share Price vs Fair Value Explore BioArctic's Fair Values from the Community and select yours Despite...Nueva narrativa • Jun 01
Regulatory Approvals And Pipeline Progress Will Redefine Neurodegeneration Care
Regulatory approvals and upcoming diagnostics are set to accelerate Leqembi adoption, expanding access and recurring royalty revenues from an underserved and growing patient base.Artículo de análisis • May 29
BioArctic's (STO:BIOA B) Solid Profits Have Weak Fundamentals
BioArctic AB (publ)'s ( STO:BIOA B ) robust earnings report didn't manage to move the market for its stock. Our...Artículo de análisis • May 16
Here's Why BioArctic AB (publ)'s (STO:BIOA B) CEO Compensation Is The Least Of Shareholders Concerns
Key Insights BioArctic will host its Annual General Meeting on 22nd of May CEO Gunilla Osswald's total compensation...Artículo de análisis • Feb 19
Need To Know: Analysts Are Much More Bullish On BioArctic AB (publ) (STO:BIOA B)
Shareholders in BioArctic AB (publ) ( STO:BIOA B ) may be thrilled to learn that the analysts have just delivered a...Artículo de análisis • Feb 18
Earnings Beat: BioArctic AB (publ) (STO:BIOA B) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
It's been a good week for BioArctic AB (publ) ( STO:BIOA B ) shareholders, because the company has just released its...Artículo de análisis • Jan 31
Analysts Just Published A Bright New Outlook For BioArctic AB (publ)'s (STO:BIOA B)
Shareholders in BioArctic AB (publ) ( STO:BIOA B ) may be thrilled to learn that the analysts have just delivered a...Artículo de análisis • Nov 27
Need To Know: Analysts Are Much More Bullish On BioArctic AB (publ) (STO:BIOA B)
Celebrations may be in order for BioArctic AB (publ) ( STO:BIOA B ) shareholders, with the analysts delivering a...Artículo de análisis • Sep 01
BioArctic AB (publ) (STO:BIOA B) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
A week ago, BioArctic AB (publ) ( STO:BIOA B ) came out with a strong set of quarterly numbers that could potentially...Artículo de análisis • Aug 15
Need To Know: The Consensus Just Cut Its BioArctic AB (publ) (STO:BIOA B) Estimates For 2024
The analysts covering BioArctic AB (publ) ( STO:BIOA B ) delivered a dose of negativity to shareholders today, by...Artículo de análisis • Apr 13
Revenues Tell The Story For BioArctic AB (publ) (STO:BIOA B)
With a price-to-sales (or "P/S") ratio of 30.5x BioArctic AB (publ) ( STO:BIOA B ) may be sending very bearish signals...Rentabilidad de los accionistas
| BIOA B | SE Biotechs | Mercado SE | |
|---|---|---|---|
| 7D | -4.4% | -3.3% | -1.6% |
| 1Y | 68.6% | 24.2% | 10.4% |
Rentabilidad vs. Industria: BIOA B superó a la industria Swedish Biotechs, que obtuvo un rendimiento del 24.2% el año pasado.
Rentabilidad vs. Mercado: BIOA B superó al mercado Swedish, que obtuvo un rendimiento del 10.4% el año pasado.
Volatilidad de los precios
| BIOA B volatility | |
|---|---|
| BIOA B Average Weekly Movement | 5.8% |
| Biotechs Industry Average Movement | 9.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in SE Market | 12.6% |
| 10% least volatile stocks in SE Market | 3.5% |
Precio estable de las acciones: BIOA B no ha tenido una volatilidad de precios significativa en los últimos 3 meses en comparación con el mercado Swedish.
Volatilidad a lo largo del tiempo: La volatilidad semanal de BIOA B (6%) se ha mantenido estable durante el año pasado.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 2000 | 141 | Gunilla Osswald | www.bioarctic.se |
BioArctic AB (publ) desarrolla en Suecia medicamentos biológicos para pacientes con trastornos del sistema nervioso central. La empresa investiga y desarrolla fármacos biológicos innovadores, como anticuerpos, que responden a necesidades médicas no cubiertas. Sus áreas terapéuticas abarcan trastornos neurodegenerativos, como la enfermedad de Alzheimer, la enfermedad de Parkinson y otras enfermedades del SNC.
Resumen de fundamentos de BioArctic AB (publ)
| Estadísticas fundamentales de BIOA B | |
|---|---|
| Capitalización bursátil | SEK 27.70b |
| Beneficios(TTM) | SEK 213.24m |
| Ingresos (TTM) | SEK 1.15b |
129.9x
Ratio precio-beneficio (PE)24.1x
Ratio precio-ventas (PS)¿Está BIOA B sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de BIOA B | |
|---|---|
| Ingresos | SEK 1.15b |
| Coste de los ingresos | SEK 67.32m |
| Beneficio bruto | SEK 1.08b |
| Otros gastos | SEK 866.53m |
| Beneficios | SEK 213.24m |
Últimos beneficios comunicados
Mar 31, 2026
Próxima fecha de beneficios
Jul 23, 2026
| Beneficios por acción (BPA) | 2.40 |
| Margen bruto | 94.13% |
| Margen de beneficio neto | 18.59% |
| Ratio deuda/patrimonio | 0% |
¿Cómo se ha desempeñado BIOA B a largo plazo?
Ver rendimiento histórico y comparativaDividendos
0.6%
Rentabilidad actual por dividendo83%
Ratio de pagosAnálisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/07/13 05:39 |
| Precio de las acciones al final del día | 2026/07/13 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
BioArctic AB (publ) está cubierta por 5 analistas. 4 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Kristofer Liljeberg-Svensson | DNB Carnegie |
| Rajan Sharma | Goldman Sachs |
| Viktor Sundberg | Nordea Markets |